A Phase IIa, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Human Mesenchymal Stem Cells to Subjects with Moderate Traumatic Brain Injury

Trial Profile

A Phase IIa, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Human Mesenchymal Stem Cells to Subjects with Moderate Traumatic Brain Injury

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 24 May 2016

At a glance

  • Drugs Ischemia-tolerant mesenchymal stem cells (Primary)
  • Indications Brain injuries
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Stemedica Cell Technologies
  • Most Recent Events

    • 24 May 2016 New trial record
    • 18 May 2016 According to a Stemedica Cell Technologies media release, company has received an FDA IND approval for this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top